CLOVER HEALTH INVESTMENTS, CORP. /DE

Annual Trend FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Depreciation and amortization expense $551k $555k $1.2m $1.2m $2.5m $1.3m $1.7m
Change in fair value of warrants and amortization of warrants $2.9m $80.3m ($66.1m) ($900k) $86k $50k $20k
Accretion, net of amortization ($2.9m) ($195k) $200k ($1.5m) ($4.0m) ($2.5m) ($1.8m)
Impairment of goodwill and other intangible assets $0 $0 $15.9m $0 $0
Net loss ($363.7m) ($6.7m) ($587.8m) ($338.8m) ($213.4m) ($43.0m) ($85.5m)
Stock-based compensation $3.3m $7.1m $163.7m $164.3m $140.9m $114.3m $103.7m
Change in accrued interest earned $0 $0 ($571k) $271k
Net realized gains on investment securities ($1.1m) $53k $267k ($20k) ($480k) ($979k)
Loss on investment $0 $0 ($9.2m) $4.7m $467k $0
Premium deficiency reserve benefit $110.6m ($93.5m) ($7.2m) $0 $0
Accrued retrospective premiums $7.5m ($21.6m) ($94k) $14.5m ($1.7m) ($19.2m) ($22.6m)
Prepaid expenses $600k ($300k) ($1.6m) ($3.4m) $3.7m $1.2m ($5.0m)
Other assets ($470k) $1.0m ($19.8m) ($1.2m) $1.8m $2.9m ($5.9m)
Healthcare receivables ($14.5m) ($12.9m) ($9.3m) ($22.6m) $6.4m $12.6m ($43.3m)
Unpaid claims $23.9m $26.1m $36.9m $2.6m ($3.6m) $19.3m ($3.1m)
Accounts payable and accrued expenses $6.3m $10.8m $5.3m $7.6m $4.7m ($2.6m) $1.6m
Accrued salaries and benefits ($2.2m) $186k $11.2m $8.8m ($2.9m) ($2.0m) ($3.1m)
Other liabilities $168k $1.4m $979k $2.5m $4.5m $606k ($2.7m)
Purchases of property and equipment ($23k) ($693k) ($723k) ($4.5m) ($584k) ($1.6m) ($2.0m)
Cash paid for shares withheld related to stock-based compensation ($6.2m) ($16.5m) ($36.9m)
Net cash (used in) provided by operating activities from continuing operations ($159.9m) ($2.2m) ($282.3m) ($304.6m) ($35.1m) $82.5m ($66.9m)
Net cash used in operating activities from discontinued operations ($159.9m) ($2.2m) ($282.3m) $100.7m ($109.5m) ($47.6m) $0
Net cash (used in) provided by operating activities ($159.9m) ($2.2m) ($282.3m) ($203.9m) ($115.9m) $34.8m ($66.9m)
Purchases of short-term investments, available-for-sale, and held-to-maturity securities ($505.5m) ($174.3m) ($876.3m) ($369.4m) ($175.6m) ($201.2m) ($205.1m)
Proceeds from sales of short-term investments and available-for-sale securities $269.2m $248.7m $126.9m $13.3m $60.4m $83.7m $185.2m
Proceeds from maturities of short-term investments and available-for-sale securities $46.4m $63.8m $314.7m $472.1m $255.7m $119.7m $26.1m
Net cash provided by investing activities ($181.9m) ($828.0m) ($435.4m) $95.1m $140.0m $565k $4.1m
Issuance of common stock, net of early exercise liability $601k $1.7m $6.1m $1.4m $1.1m $709k $718k
Issuance of common stock under employee stock purchase plan, net of stock issuance costs $0 $25k $283.8m $0 $0 $193k $1.1m
Repurchases of common stock $0 $0 ($147k) ($6.4m) ($6.2m) ($1.8m) ($18.3m)
Net cash used in financing activities $334.0m $858.2m $925.4m ($5.0m) ($33.9m) ($17.4m) ($53.4m)
Net (decrease) increase in cash and cash equivalents ($7.8m) $24.8m $207.6m ($113.8m) ($9.7m) $18.0m ($116.2m)
Cash and cash equivalents, beginning of period $67.6m $92.3m $300.0m $186.2m $176.5m $194.5m $78.3m
Cash and cash equivalents $28.0m $300.0m $103.8m $122.9m $194.5m $78.3m
Restricted cash $0 $0 $82.4m $53.6m $0 $0

Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.